Focus Stocks
Forest Laboratories Expecting a Break Out?
Published on Tuesday, 24 January 2012 07:48 Written by TradersHuddle Staff
New York, January 24th (TradersHuddle.com) - Shares of Forest Laboratories, Inc. (NYSE:FRX) closed the trading session at $32.14 near its 200 day moving average currently set at $33.46. Forest Laboratories' price action is below this important level, which makes the stock difficult to buy, as there will certainly be resistance as it approaches its 200 day moving average.
Forest Laboratories, Inc. (NYSE:FRX) develops, manufactures, and sells branded and generic forms of ethical drug products. The Company also manufactures non-prescription pharmaceutical products sold over-the-counter, which are used for the treatment of a wide range of illnesses.
Latest price action range, defined by a peaks and troughs algorithm places calculated support at $28.47 and calculated resistance at $32.37. These levels are being closely watched by traders, as they provide great reference points for the latest price dynamics in Forest Laboratories shares.
Traders should evaluate their trade if they want to establish a position on Forest Laboratories given the resistance could materialize as the stock approaches the 200 day moving average. A trade might materialize as the stock manages to break this important level, as it could be used as support going forward, however until the break materializes, traders need to exercise patience. Other levels that traders will be evaluating are the ones defined by the peak and troughs algorithm that provides great price action reference points.
Related Articles
- Forest and Almirall to Present Aclidinium Bromide Clinical Data at the American Thoracic Society (ATS) International Conference
- Forest Laboratories, Inc. to Present Cariprazine and Levomilnacipran Results from Phase 3 Trials at American Psychiatric Association (APA) Annual Meeting
- New Ratings ( FRX, NEPT, PDCO )
- Forest Laboratories, Inc. and Pierre Fabre Medicament Announce Third Positive Phase III Study for Levomilnacipran in Patients with Major Depressive Disorder
- Ironwood and Forest Announce FDA Has Extended the Review Period for Linaclotide to September 2012
- Forest Laboratories, Inc. to Host Investor Meeting to Review Company’s Late-Stage Product Development Pipeline and Commercialization Strategy
- Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2012 Earnings Per Share of $0.72 Including $0.06 Per Share of Acquisition Amortization
- Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2012 Fourth Quarter Earnings
- Forest Laboratories, Inc. Announces Buyout of Bystolic Royalties from Janssen Pharmaceutica NV
- Forest Laboratories and Almirall Announce FDA has Extended the Review Period for Aclidinium Bromide
Related Partner Headlines
- Think Like the Father of Value Investing - TheStreet.com
- Notable Call Options Activity in Forest Laboratories - Benzinga
- Forest Laboratories and Pierre Fabre Medicament Announce Positive Phase III Results For Levomilnacipran in Patients with Major Depressive Disorder - Benzinga
- From Earlier: Forest Laboratories, Inc. and Gedeon Richter Announce Results from Two Positive Phase III Trials with the Investigational Antipsychotic Cariprazine for the Treatment of Schizophrenia - Benzinga
- From Earlier: Forest Laboratories Receives European Marketing Approval for Colobreathe Dry Powder Inhaler - Benzinga
- From Earlier: Forest and Almirall Announce Positive FDA Advisory Committee's Recommendation for Approval of Aclidinium Bromide for the Treatment of Chronic Obstructive Pulmonary Disease - Benzinga
- Analysts' Actions: GOOG, FRX, JBHT, KSU - TheStreet.com
- Forest Labs Posts Weak Quarter - TheStreet.com
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Recent Trading Ideas
-
The 200 Day Moving Average is Key for Baxter International -
Barrick Gold Broke Resistance -
Molson Coors Brewing is Near a Key Support Area -
Is Cisco Closing in to Support? -
BB&T near Support -
Close to the 50 Day Moving Average: American Tower -
Trading Idea: What to Expect as Chesapeake Energy Breaks Resistance
Latest Partner Headlines
-
Stock Futures Rise on Eurobond Talk - TheStreet.com -
You Can Let Your Guard Down: Ask Noah - TheStreet.com -
Apple Strengthens Its Supply Chain - TheStreet.com -
NYSE Is Winning the IPO Listing War - TheStreet.com -
Toyota Is Back as May Sales Continue Auto Industry Recovery - TheStreet.com -
One Emotional Market - TheStreet.com -
Mixed Signals Emerge From Bakken Shale - TheStreet.com -
The Five Dumbest Things on Wall Street This Week: May 25 - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,529.75 Trade time:4:05PM EDT Value change:▲33.60 (0.27%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,320.68 Trade time:4:32PM EDT Value change:▲1.82 (0.14%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,839.38 Trade time:5:16PM EDT Value change:▼10.74 (-0.38%)In The Wires
-
Government of Rwanda Introduces Merck's ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus -
Continental Resources Names Kirk Kinnear as Vice President of Oil Marketing Logistics -
Charm Communications to Present at Three Conferences in June -
Senior Management at UVMF Prepares to Pitch Some Big Ideas to Facebook -
XPO Logistics to Participate in Investor Conferences -
IntercontinentalExchange Announces Record Brent Crude Option Volume -
Grand Reopening Weekend Set for Newly Remodeled Life Time Fitness Six Forks Center May 26-27 -
Unwired Planet Takes Flight With a Tribute to Our Inventors and Their Impact on the Mobile Internet









